E09 [3-hydroxy-5-azinrdinyl-l-methyl-2( 1 H-indole4.7-dione)-prop-fren-a-ol] was selected for clinical tnral in Europe because of its preclinical profile but also because of its distinct mechanism of bioactivation. Several studies have shown that cells rich in DT-diaphorase may be particularly sensitive to E09-The present study examined the relationship between DT-diaphorase activity and sensitivity to E09 in a panel of cell lines largely derived from human and rodent leukaemias lymphoma and solid tumours (Collard et al., 1993) . The present study examined initially the relationship between levels of DT-diaphorase and sensitivity to E09 in a panel of cell lines derived from rodent and human leukaemias and solid tumours and hamster fibroblasts. A number of the human lines were subsequently established as xenografts in nude mice and tumour levels of DT-diaphorase and sensitivity to E09 determined in vivo. The aims of these studies were to investigate whether cell lines reflected the solid tumour levels of DT-diaphorase and also to determine whether it was possible to predict in vivo sensitivity to E09 on the basis of enzyme level.
under the auspices of the EORTC New Drug Development Coordinating Committee and EORTC New Drug Development Office. It was selected for clinical study because of its distinct mechanism of bioactivation. its activity against hypoxic cells, its preferential solid tumour activity and its lack of bone marrow toxicity in animal studies (Hendricks et al., 1993) . Bioreductive activation is thought to play a major role in the mechanism of action of E09. The compound has been shown to be a good substrate for reduction by human and rodent DT-diaphorase [NAD(P)H: (quinone acceptor) oxoreductase, EC 1.6. 99.2]. The two-electron reduction of E09 via DT-diaphorase generates DNA-damaging species in vitro (Walton et al.. 1991) , and experiments performed with DT-diaphorase-rich Walker tumour cells showed development of DNA single-strand breaks and cross-links after exposure to E09 (Bailey et al., 1992) .
These studies suggest that cells nrch in DT-diaphorase may be particularly sensitive to E09. Because of the small number of studies describing relative expression of enzyme in tumour vs normal tissue (Riley and Workman, 1992) and preliminary observations demonstrating a correlation between E09 sensitivity and DT-diaphorase expression in murine colon tumours (Walton et al., 1992) , there is a need for further work in this area. A number of groups have now attempted to correlate sensitivity to E09 with DT-diaphorase expression in panels of cell lines in vitro. Collard and Double (1992) described three human cell lines with similar IC_% values for E09 chemosensitivity but that had a 1500-fold difference in enzyme activity. Robertson et al. (1992) (Collard et al., 1993) . The present study examined initially the relationship between levels of DT-diaphorase and sensitivity to E09 in a panel of cell lines derived from rodent and human leukaemias and solid tumours and hamster fibroblasts. A number of the human lines were subsequently established as xenografts in nude mice and tumour levels of DT-diaphorase and sensitivity to E09 determined in vivo. The aims of these studies were to investigate whether cell lines reflected the solid tumour levels of DT-diaphorase and also to determine whether it was possible to predict in vivo sensitivity to E09 on the basis of enzyme level.
Materials and metbods
Chemicals E09 was synthesised originally by Oostveen and Speckamp (1987) Results of in vivo investigations are presented in Table II . For the human tumour xenografts successfully established in vivo tumour volume doubling times ranged from 4 to 14 days. With the exception of HT29. each of the solid tumours demonstrated greatly reduced DT-diaphorase specific activity compared with the cell lines, and almost all failed to respond significantly to E09. One breast cancer cell line which was established as a xenograft (MVBO) had particularly low enzyme activity but unfortunately failed to grow in long-term cell culture. It did not respond significantly to E09 in vivo. HT29 possessed similar enzyme activity when grown as a cell line or as a solid tumour in nude mice. but even though the cell line was quite sensitive to E09 the solid tumour failed to respond. Further studies using a daily dose schedule (6 mg kg-'. i.v.) failed to produce measurable anti-tumour effects even though there was considerable body weight loss (>10%) and 1 9 deaths in the treated group. A preliminary study designed to evaluate the potential of hourly scheduling against HT29 examined 6 mg kg'. i.v.. hourly for 3 h. This treatment resulted in 30% mean tumour inhibition on day 7 (calculated from tumour volumes from control and treated mice) but only 2 10 mice survived until day 14 after treatment. The only tumour xenograft of the series to show measurable growth delay following single-dose E09 treatment was HCLO (Table II) . Effects against this tumour were quite good. with the 10 day growth delay representing 2.5 times the volume doubling time of the tumour. DTdiaphorase activity in the HCLO tumour, however, was shown to be low.
Discussion
This study set out to examine the relationship between levels of DT-diaphorase and sensitivity to E09 in vitro and in vivo.
Correlation between DT-diaphorase activity and IC50 values in vitro was reasonable, confirming the observations of Robertson et al. (1994) and Smitskamp-Wilms et al. (1994) (Phillips et al.. 1992) . Even taking this into account, the duration of exposure may still be too long to mimic that achievable in vivo. The importance of exposure time for anti-tumour effects might best be demonstrated in vitro by the use of much shorter drug exposure times than those employed here. The preliminary hourly dosing schedule suggests that it may be possible to obtain responses by optimising drug doses and schedules, but whether this can be achieved in the absence of normal tissue toxicity needs to be established. Hendriks et al. (1993) showed that the activity of E09 against the MRI-H-207 human ovarian xenograft was similar when single intraperitoneal administration on day 0 and day 7 was compared with an every hour x 6 schedule; but the hourly schedule appeared less toxic. Studies by Adams et al. (1992) demonstrated that E09 was inactive against the KHT sarcoma in mice but the compound could potentiate the action of 10 Gy X-irradiation. This dose of radiation is sufficient to eradicate the aerobic fraction, implying that E09 can work as a hypoxic toxin in vivo and may well be effective in combination with other modalities.
In conclusion, this study has demonstrated a relationship between DT-diaphorase activity and chemosensitivity to E09 in a panel of rodent and human cell lines. In general, the cell lines which possess high levels of DT-diaphorase tend to be the most responsive to E09. With the exception of HT29, human tumour xenografts in nude mice. developed from a number of these cell lines, had much less DT-diaphorase activity than the corresponding cell line. Only HCLO responded to single-dose E09, and this tumour was low in DT-diaphorase activity. Attempts to optimise drug exposure parameters in tumours with high enzyme activity are currently ongoing.
